Injectable depot compositions and uses thereof

• US 8,252,303 B2
• Filed: 11/14/2002
• Issued: 08/28/2012
• Est. Priority Date: 07/31/2002
• Status: Expired due to Fees

• Current Assignee: DURECT Corporation
• Original Assignee: DURECT Corporation
• Inventors: Chen, Guohua, Houston, Paul R., Kleiner, Lothar Walter, Spaltro, John J.
• Primary Examiner(s): Fubara, Blessing
• Application Number:
  US10/295,814
• Publication Number:
  US 20040024069A1
• Time in Patent Office: 3,575 Days
• Field of Search: 424/426, 424/489, 424/423, 514/772.3
• US Class Current: 424/426
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 38/1858 Platelet-derived growth factor [PDGF]
• CPC Class Codes: A61K 38/27 Growth hormone [GH], i.e. somatotropin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/14 Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0002 Galenical forms characterised by the drug release technique; Application systems commanded by energy
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/1617 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Injectable depot compositions are provided that include a bioerodible, biocompatible polymer, a solvent having a miscibility in water of less than or equal to 7 wt. % at 25° C., in an amount effective to plasticize the polymer and form a gel therewith, a thixotropic agent, and a beneficial agent. The solvent comprises an aromatic alcohol, an ester of an aromatic acid, an aromatic ketone, or mixtures thereof. The compositions have substantially improved the shear thinning behavior and reduced injection force, rendering the compositions readily implanted beneath a patient'"'"'s body surface by injection.

Claims

1. An injectable depot composition comprising:

(a) a bioerodible, biocompatible polymer;

(b) a solvent selected from the group consisting of aromatic alcohols, esters of aromatic acids, aromatic ketones, and mixtures thereof, said solvent having a miscibility in water of less than or equal to 7% at 25°

C., and present in an amount effective to plasticize the polymer and form a gel therewith;

(c) a thixotropic amount of a thixotropic agent mixed with the polymer effective to form a thixotropic composition, the thixotropic agent comprising a lower alkanol and said amount being between 0.01 weight percent and 15 weight percent of the combined weight of the solvent and the thixotropic agent; and

(d) a beneficial agent;

wherein the injectable depot composition does not comprise an emulsion.

2. The injectable depot composition of claim 1, wherein the solvent is a mixture of the aromatic alcohol and the ester of the aromatic acid.

3. The injectable depot composition of claim 2, wherein the aromatic alcohol is benzyl alcohol and the ester of the aromatic acid is a lower alkyl ester or an aralkyl ester of benzoic acid.

4. The injectable depot composition of claim 3, wherein the ester of the aromatic acid is benzyl benzoate and the lower alkyl ester of the aromatic acid is ethyl benzoate.

5. An injectable depot composition comprising:

(a) approximately 5 wt. % to approximately 90 wt. % of a biodegradable, biocompatible lactic acid-based polymer having an average molecular weight in the range of approximately 1,000 to approximately 120,000;

(b) a solvent selected from the group consisting of an aromatic alcohol, an ester of an aromatic acid, and mixtures thereof, said solvent having a miscibility in water of less than or equal to 7% at 25°

C., and present in an amount effective to plasticize the polymer and form a gel therewith, wherein the aromatic alcohol has the structural formula (I)

Ar-(L)_n-OH 

 

(I)

in which Ar is a substituted or unsubstituted aryl or heteroaryl group, n is zero or 1, and L is a linking moiety;

(c) a thixotropic amount of a thixotropic agent mixed with the polymer effective to form a thixotropic composition, the thixotropic agent comprising a lower alkanol and said amount being between 0.01 Weight percent and 15 weight percent of the combined weight of the solvent and the thixotropic agent; and

(d) a beneficial agent;

wherein the injectable depot composition does not comprise an emulsion.

6. The injectable depot composition of claim 5, wherein the solvent is a mixture of the aromatic alcohol and the ester of the aromatic acid.

7. The injectable depot composition of claim 6, wherein the aromatic alcohol is benzyl alcohol and the ester of the aromatic acid is a lower alkyl ester or an aralkyl ester of benzoic acid.

8. The injectable depot composition of claim 7, wherein the ester of the aromatic acid is benzyl benzoate and the lower alkyl ester of the aromatic acid is ethyl benzoate.

9. The injectable depot composition of claim 8, wherein the thixotropic agent is ethanol.

10. The injectable depot composition of claim 6, wherein a ratio of the aromatic alcohol to the ester of the aromatic acid is in the range of about 1% to about 99% by weight.

11. The injectable depot composition of claim 10, wherein the ratio of the aromatic alcohol to the ester of the aromatic acid is in the range of about 20% to about 80% by weight.

12. The injectable depot composition of claim 5, wherein the beneficial agent is selected from a drug, proteins, enzymes, hormones, polynucleotides, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, polypeptides, steroids, analgesics, local anesthetics, antibiotic agents, chemotherapeutic agents, immunosuppressive agents, anti-inflammatory agents, antiproliferative agents, antimitotic agents, angiogenic agents, anticoagulants, fibrinolytic agents, growth factors, antibodies, and ocular drugs.

13. The injectable depot composition of claim 12, wherein the beneficial agent is a growth factor.

14. The injectable depot composition of claim 12, wherein the beneficial agent is present in an amount of from 0.1 to 50% by weight of the combined amounts of the polymer, the solvent and the beneficial agent.

15. The injectable depot composition of claim 12, wherein the beneficial agent is in a form of particles dispersed or dissolved in the gel.

16. The injectable depot composition of claim 15, wherein the beneficial agent is in the form of the particles having an average particle size of from 0.1 to 250 microns.

17. The injectable depot composition of claim 15, wherein the beneficial agent is in the form of the particles, wherein the particles further comprise a component selected from the group consisting of a stabilizing agent, bulking agent, chelating agent, and buffering agent.

18. The injectable depot composition of claim 5, wherein the beneficial agent is a growth hormone.

19. An injectable depot composition comprising:

(a) approximately 5 wt. % to approximately 90 wt. % of a poly(lactide-co-glycolide) (PLGA) copolymer having an average molecular weight in the range of approximately 1,000 to approximately 120,000;

(b) approximately 5 wt. % to approximately 90 wt. % of a solvent selected from the group consisting of an aromatic alcohol, an ester of an aromatic acid, and mixtures thereof, said solvent having a miscibility in water of less than or equal to 7% at 25°

C., and present in an amount effective to plasticize the polymer and form a gel therewith;

(c) a thixotropic amount of a thixotropic agent mixed with the polymer effective to form a thixotropic composition, wherein the thixotropic agent is ethanol and an amount of ethanol is greater than or equal to 0.01 weight percent and less than or equal to 15 weight percent of the combined weight of the solvent and the thixotropic agent; and

(d) a beneficial agent;

wherein the injectable depot composition does not comprise an emulsion.

20. The injectable depot composition of claim 19, wherein the aromatic alcohol is benzyl alcohol and the ester of the aromatic acid is benzyl benzoate.

21. A method of administering a beneficial agent to a subject comprising:

(1) administering an injectable depot composition to the subject at a site within the subject, the composition comprising;

(a) a bioerodible, biocompatible polymer;

(b) a solvent selected from the group consisting of aromatic alcohols, esters of aromatic acids, aromatic ketones, and mixtures thereof, said solvent having a miscibility in water of less than or equal to 7% at 25°

C., and present in an amount effective to plasticize the polymer and form a gel therewith;

(c) a thixotropic amount of a thixotropic agent mixed with the polymer effective to form a thixotropic composition, the thixotropic agent comprising a lower alkanol and said amount being less than 15 weight percent of the combined weight of the solvent and the thixotropic agent; and

(d) a beneficial agent; and

(2) forming an implant at the site wherein the implant provides sustained release of the beneficial agent at the site;

wherein the injectable depot composition does not comprise an emulsion.

22. The method of claim 21, wherein the solvent is a mixture of the aromatic alcohol and the ester of the aromatic acid.

23. The method of claim 22, wherein the aromatic alcohol is benzyl alcohol and the ester of the aromatic acid is a lower alkyl ester or an aralkyl ester of benzoic acid.

24. The method of claim 23, wherein the ester of the aromatic acid is benzyl benzoate and the lower alkyl ester of the aromatic acid is ethyl benzoate.

25. A method of administering a beneficial agent to a subject to provide sustained release of the beneficial agent to the subject, the method comprising:

(1) administering an injectable depot composition to the subject at a site within the subject, the composition comprising;

(a) approximately 5 wt. % to approximately 90 wt. % of a biodegradable, biocompatible lactic acid-based polymer having an average molecular weight in the range of approximately 1,000 to approximately 120,000;

(b) a solvent selected from the group consisting of an aromatic alcohol, an ester of an aromatic acid, and mixtures thereof, said solvent having a miscibility in water of less than or equal to 7% at 25°

C., and present in an amount effective to plasticize the polymer and form a gel therewith, wherein the aromatic alcohol has the structural formula (I)

Ar-(L)_n-OH 

 

(I)

 

in which Ar is a substituted or unsubstituted aryl or heteroaryl group, n is zero or 1, and L is a linking moiety;

(c) a thixotropic amount of a thixotropic agent mixed with the polymer effective to form a thixotropic composition, the thixotropic agent comprising a lower alkanol and said amount being less than 15 weight percent of the combined weight of the solvent and the thixotropic agent; and

(d) a beneficial agent; and

(2) forming an implant at the site wherein the implant provides sustained release of the beneficial agent at the site;

wherein the injectable depot composition does not comprise an emulsion.

26. The method of claim 25, wherein the solvent is a mixture of the aromatic alcohol and the ester of the aromatic acid.

27. The method of claim 26, wherein the aromatic alcohol is benzyl alcohol and the ester of the aromatic acid is a lower alkyl ester or an aralkyl ester of benzoic acid.

28. The method of claim 27, wherein the ester of the aromatic acid is benzyl benzoate and the lower alkyl ester of the aromatic acid is ethyl benzoate.

29. The method of claim 28, wherein a ratio of the aromatic alcohol to the ester of the aromatic acid is in the range of about 1% to about 99% by weight.

30. The method of claim 29, wherein the ratio of the aromatic alcohol to the ester of the aromatic acid is in the range of about 20% to about 80% by weight.

31. The method of claim 27, wherein the thixotropic agent is ethanol.

32. The method of claim 25, wherein the thixotropic agent is ethanol.

33. The method of claim 32, wherein an amount of the ethanol is greater than or equal to 0.01 weight percent and less than or equal to 15 weight percent of the combined weight of the solvent and the thixotropic agent.

34. The method of claim 33, wherein the amount of the ethanol is greater than or equal to 0.1 weight percent and less than or equal to 5 weight percent of the combined weight of the solvent and the thixotropic agent.

35. The method of claim 34, wherein the amount of ethanol is greater than or equal to 0.5 weight percent and less than or equal to 5 weight percent of the combined weight of the solvent and the thixotropic agent.

36. The method of claim 25, wherein the beneficial agent is selected from a drug, proteins, enzymes, hormones, polynucleotides, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, polypeptides, steroids, analgesics, local anesthetics, antibiotic agents, chemotherapeutic agents, immunosuppressive agents, anti-inflammatory agents, antiproliferative agents, antimitotic agents, angiogenic agents, anticoagulants, fibrinolytic agents, growth factors, antibodies, and ocular drugs.

37. The method of claim 36, wherein the beneficial agent is a growth factor.

38. The method of claim 36, wherein the beneficial agent is present in an amount of from 0.1 to 50% by weight of the combined amounts of the polymer, the solvent and the beneficial agent.

39. The method of claim 36, wherein the beneficial agent is in a form of particles dispersed or dissolved in the gel.

40. The method of claim 39 wherein the beneficial agent is in the form of the particles, wherein the particles further comprise a component selected from the group consisting of a stabilizing agent, bulking agent, chelating agent, and buffering agent.

41. The method of claim 36, wherein the beneficial agent is in the form of the particles having an average particle size of from 0.1 to 250 microns.

42. The method of claim 25, wherein the beneficial agent is a growth hormone.

43. A method of administering a beneficial agent to a subject to provide sustained release of the beneficial agent to the subject, the method comprising:

(1) administering an injectable depot composition to the subject at a site within the subject, the composition comprising;

(a) approximately 5 wt. % to approximately 90 wt. % of a poly(lactide-co-glycolide) (PLGA) copolymer having an average molecular weight in the range of approximately 1,000 to approximately 120,000;

(b) approximately 5 wt. % to approximately 90 wt. % of a solvent selected from the group consisting of an aromatic alcohol, an ester of an aromatic acid, and mixtures thereof, said solvent having a miscibility in water of less than or equal to 7% at 25°

C., and present in an amount effective to plasticize the polymer and form a gel therewith,

(c) a thixotropic amount of a thixotropic agent mixed with the polymer effective to form a thixotropic composition, wherein the thixotropic agent is ethanol and an amount of ethanol is greater than or equal to 0.01 weight percent and less than or equal to 15 weight percent of the combined weight of the solvent and the thixotropic agent; and

(d) a beneficial agent; and

(2) forming an implant at the site wherein the implant provides sustained release of the beneficial agent at the site;

wherein the injectable depot composition does not comprise an emulsion.

44. The method of claim 43, wherein the aromatic alcohol is benzyl alcohol and the ester of the aromatic acid is benzyl benzoate.